Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors has appointed Ellen R. Hoffing as a new director of the Company.
Joseph C. Papa, Perrigo's Chairman, President and Chief Executive Officer, stated, "Ellen Hoffing's outstanding background has served her well in leadership roles at several pharmaceutical and healthcare companies. Her broad business and strategic acumen will allow her to make excellent contributions to our Board. We are pleased to welcome Ellen to the Perrigo Board of Directors."
Since 2006, Ellen R. Hoffing, 51, has served as President and Chief Executive Officer of Applied NeuroSolutions, Inc., a development stage biopharmaceutical company focused on diagnostics and therapeutics for the treatment of Alzheimer's Disease. She has also served as Chairman of Applied NeuroSolutions' Board of Directors since December 2007. Ms. Hoffing has extensive experience in the pharmaceutical industry, including management, strategic planning and operations, given her prior senior positions at American Pharmaceutical Partners (2005-2006), Baxter Healthcare (2002-2005), and Searle Pharmaceuticals (1983-2000). Ms. Hoffing has a bachelor of science in accountancy from the University of Illinois at Urbana -- Champaign and a masters in management from the Kellogg Graduate School of Management at Northwestern University.
Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet ( http://www.perrigo.com/ ).
Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2007, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
First Call Analyst:
FCMN Contact: penny.bursma@perrigo.com
SOURCE: Perrigo Company
CONTACT: Arthur J. Shannon, Vice President, Investor Relations and
Communication, Perrigo Company, +1-269-686-1709, ajshannon@perrigo.com
Web site: http://www.perrigo.com/